Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | NCF1 | P14598 | 2/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29935705 | 1.00 | CYP1A2 (0.63) | CYP1A2NCF1ERN1L3MBTL1MEN1 | |
| SCHEMBL28910002 | 0.81 | LMNA (0.58) | CYP1A2L3MBTL1MEN1KMT2AHTT | |
| SCHEMBL11810842 | 0.81 | CYP1A2 (0.58) | CYP1A2NCF1L3MBTL1MEN1KMT2A | |
| SCHEMBL6789068 | 0.81 | NCF1 (0.59) | CYP1A2NCF1L3MBTL1MEN1KMT2A | |
| SCHEMBL19651360 | 0.81 | NPC1 (0.44) | CYP1A2ERN1MEN1KMT2ABACE1 | |
| SCHEMBL18391405 | 0.79 | CYP1A2 (0.55) | CYP1A2NCF1L3MBTL1MEN1KMT2A | |
| SCHEMBL6789373 | 0.79 | CYP1A2 (0.55) | CYP1A2NCF1L3MBTL1MEN1KMT2A | |
| SCHEMBL28910016 | 0.79 | CASP3 (0.45) | CYP1A2KDM4EALDH1A1 | |
| SCHEMBL6788656 | 0.79 | CYP1A2 (0.55) | CYP1A2NCF1L3MBTL1MEN1KMT2A | |
| SCHEMBL29502790 | 0.78 | CYP1A2 (1.00) | CYP1A2NCF1L3MBTL1KMT2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| WO-2023008577-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | 国立大学法人神戸大学 | 2023-02-02 | — | — | WO | disclosed |
| CN-115335378-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-109608435-B | Quinoline substituted indole compound, preparation method and application thereof | 中国药科大学 | 2021-10-29 | — | — | CN | disclosed |
| CN-109467549-B | Quinoline-substituted chalcone compound, preparation method and application thereof | 中国药科大学 | 2021-02-09 | — | — | CN | disclosed |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| CN-109467549-A | Quinoline replaces chalcone compounds, preparation method and the usage | 中国药科大学 | 2019-03-15 | — | — | CN | disclosed |
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2017-08-31 | — | — | US | disclosed |
| EP-2699569-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| WO-2003011868-A1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
| EP-0975602-A4 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | GRUENENTHAL GMBH (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-02-14 | — | — | US | disclosed |
| US-6294566-B1 | ENANTIOMORPHS REVERSE AND ADRENERGIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-09-25 | — | — | US | disclosed |
| US-6093727-A | A SELECTIVE AGONISTS FOR HUMAN ALPHA 2 RECEPTORS FOR TREATING DISORDERS AS HYPERTENSION, PAIN, GLAUCOMA, ALCOHOL AND DRUG WITHDRAWAL, ISCHEMIA, RHEUMATOID ARTHRITIS, MIGRAINE, COGNITIVE DEFICIENCY, SPASTICITY, DIARRHEA, NASAL CONGESTION | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-0975602-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5866579-A | SELECTIVE AGONISTS FOR CLONED HUMAN ALPHA-2 ADRENERGIC RECEPTORS. | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998046572-A1 | IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-10-22 | — | — | WO | disclosed |
| EP-0096214-B1 | ANTIBACTERIAL PYRIMIDINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-02-27 | — | — | EP | disclosed |
| EP-0096214-A1 | Antibacterial pyrimidine compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | CYP1A2 3211/4885NCF1 3843/4885ERN1 638/4885 |
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | CYP1A2 3982/4885NCF1 708/4885ERN1 1375/4885 |
| US-20020019390-A1 | Imidazole and imidazoline derivatives and uses thereof | ADRB2, ADRA2C, ADRB3 | CYP1A2 178/4885NCF1 3979/4885ERN1 3816/4885 |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | PIM1, PIM2, PIM3 | CYP1A2 2996/4885NCF1 3709/4885ERN1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.